U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known			
				Application Number	09/757,688		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	January 11, 2001		
				First Named Inventor	Wolfgang Heil		
				Art Unit	1611		
(Use as many sheets as necessary)				Examiner Name	Channavajjala, Lakshmi Sarada		
Sheet	1	of	1	Attorney Docket Number	PLOVIN-0002-A		

	U.S. PATENT DOCUMENTS						
Examiner	Cite	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant		
Initials *	No.1	Number - Kind Code ² (<i>if known</i>)	MM-DD-YYYY		Passages or Relevant Figures Appear		
		US-4,291,029	09-22-1981	Weichert et al.			
		US-					
		US-					
		US-					
		US-					

FOREIGN PATENT DOCUMENTS						
Examiner Cite No.1	Cito	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Country Code ³ - Number ⁴ - Kind Code ⁵ (<i>if known</i>)	Date MM-DD-YYYY	Applicant of Cited Document		T ⁶
		JP 8-325146	12-10-1996			Partial
		WO 99/02665	01-21-1999	Nanosystems LLC		Х

NON PATENT LITERATURE DOCUMENTS					
Examiner Cite the item (book, magazine, journal, serial, symposium, catalog,		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
		AULTON, MICHAEL E., "Pharmaceutics: The Science of Dosage Form Design", 1988, Chapter 1, pp. 1-13 and Chapter 9, pp. 135-173.			
		KRAUSE, W et al., "Pharmacokinetics of the New Aldosterone Antagonist, Spirorenone, in Healthy Volunteers After Single and Repeated Daily Doses", European Journal of Clinical Pharmacology, 1983, pp. 231-236.			

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.